List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1540600/publications.pdf Version: 2024-02-01



Ειμ Ματειμιρα

#	Article	IF	CITATIONS
1	High Prevalence of HTLV-1 Carriers Among the Elderly Population in Kagoshima, a Highly Endemic Area in Japan. AIDS Research and Human Retroviruses, 2022, 38, 363-369.	0.5	2
2	Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P). Viruses, 2022, 14, 136.	1.5	15
3	An NEFH founder mutation causes broad phenotypic spectrum in multiple Japanese families. Journal of Human Genetics, 2022, 67, 399-403.	1.1	5
4	Complex hereditary peripheral neuropathies caused by novel variants in mitochondrial-related nuclear genes. Journal of Neurology, 2022, 269, 4129-4140.	1.8	2
5	A Novel 89Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): "Lactosome―Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy. Life, 2021, 11, 158.	1.1	7
6	Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases. Cells, 2021, 10, 707.	1.8	4
7	Genome wide association study of HTLV-1–associated myelopathy/tropical spastic paraparesis in the Japanese population. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	9
8	Anti-Human T-Cell Leukemia Virus Type 1 (HTLV-1) Antibody Assays in Cerebrospinal Fluid for the Diagnosis of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Journal of Clinical Microbiology, 2021, 59, .	1.8	3
9	The application of shotgun metagenomics to the diagnosis of granulomatous amoebic encephalitis due to Balamuthia mandrillaris: a case report. BMC Neurology, 2021, 21, 392.	0.8	9
10	Rapid and specific detection of oxidized LDL/β2GPI complexes via facile lateral flow immunoassay. Heliyon, 2020, 6, e04114.	1.4	3
11	Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. PLoS Neglected Tropical Diseases, 2020, 14, e0008361.	1.3	5
12	<i>Tithonia diversifolia</i> â€derived orizabin suppresses cell adhesion, differentiation, and oxidized LDL accumulation by Akt signaling suppression via PTEN promotion in THPâ€1 cells. Journal of Food Biochemistry, 2020, 44, e13268.	1.2	2
13	Sera Anti-P53 Antibody Provides New Information Which Explains the Link Between Diabetes and Cancer. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 325-331.	1.1	1
14	Antioxidative attributes of rice bran extracts in ameliorative effects of atherosclerosis-associated risk factors. Heliyon, 2020, 6, e05743.	1.4	10
15	Novel singleâ€chain variant of antibody against mesothelin established by phage library. Cancer Science, 2019, 110, 2722-2733.	1.7	10
16	Clinical and genetic features of Charcotâ€Marieâ€īooth disease 2F and hereditary motor neuropathy 2B in Japan. Journal of the Peripheral Nervous System, 2018, 23, 40-48.	1.4	17
17	Mutations in COA7 cause spinocerebellar ataxia with axonal neuropathy. Brain, 2018, 141, 1622-1636.	3.7	38
18	Mutants of β2-glycoprotein I: Their features and potent applications. Best Practice and Research in Clinical Rheumatology, 2018, 32, 572-590.	1.4	3

#	Article	IF	CITATIONS
19	Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. Acta Neuropathologica Communications, 2018, 6, 105.	2.4	34
20	PET Imaging Utilizing <sup>89</sup> Zr-labeled Human Antibody Variant and Theranostic Technologies Provided by a Novel DDS Carrier. Drug Delivery System, 2018, 33, 214-222.	0.0	1
21	Peripheral neuropathy in a case with CADASIL: a case report. BMC Neurology, 2018, 18, 134.	0.8	0
22	<i>Toxocara canis</i> myelitis involving the lumbosacral region: a case report. Journal of Spinal Cord Medicine, 2017, 40, 241-245.	0.7	9
23	In vivo distribution of single chain variable fragment (scFv) against atherothrombotic oxidized LDL/l²2-glycoprotein I complexes into atherosclerotic plaques of WHHL rabbits: Implication for clinical PET imaging. Autoimmunity Reviews, 2017, 16, 159-167.	2.5	11
24	Anti-high Mobility Group Box 1 Antibody Ameliorates Albuminuria in MRL/lpr Lupus-Prone Mice. Molecular Therapy - Methods and Clinical Development, 2017, 6, 31-39.	1.8	15
25	The lipid moiety 7-ketocholesteryl-9-carboxynonanoate mediates binding interaction of oxLDL to LOX-1 and upregulates ABCA1 expression through PPARÎ <sup>3</sup> . Life Sciences, 2017, 177, 27-40.	2.0	8
26	Effects of host restriction factors and the HTLV-1 subtype on susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology, 2017, 14, 26.	0.9	20
27	Dynamic acquisition of HTLV-1 tax protein by mononuclear phagocytes: Role in neurologic disease. Journal of Neuroimmunology, 2017, 304, 43-50.	1.1	3
28	The CC chemokine ligand (CCL) 1, upregulated by the viral transactivator Tax, can be downregulated by minocycline: possible implications for long-term treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis. Virology Journal, 2017, 14, 234.	1.4	9
29	Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. Oncotarget, 2017, 8, 21177-21186.	0.8	20
30	Cytoprotective and Cytotoxic Effects of Rice Bran Extracts in Rat H9c2(2-1) Cardiomyocytes. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-12.	1.9	7
31	Enhanced cellular uptake of lactosomes using cell-penetrating peptides. Science and Technology of Advanced Materials, 2016, 17, 245-252.	2.8	14
32	HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): A comparative study to identify factors that influence disease progression. Journal of the Neurological Sciences, 2016, 371, 112-116.	0.3	44
33	Mutations in <i>MME</i> cause an autosomalâ€recessive Charcot–Marie–Tooth disease type 2. Annals of Neurology, 2016, 79, 659-672.	2.8	82
34	Endemic impact of human T cell leukemia virus type 1 screening in bone allografts. Cell and Tissue Banking, 2016, 17, 555-560.	0.5	1
35	Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer. Oncotarget, 2016, 7, 33025-33034.	0.8	9
36	A Novel PET Imaging Using <sup><b>64</b></sup> Cu-Labeled Monoclonal Antibody against Mesothelin Commonly Expressed on Cancer Cells. Journal of Immunology Research, 2015, 2015, 1-15.	0.9	32

#	Article	IF	CITATIONS
37	Visualization of HTLV-1–Specific Cytotoxic T Lymphocytes in the Spinal Cords of Patients With HTLV-1–Associated Myelopathy/Tropical Spastic Paraparesis. Journal of Neuropathology and Experimental Neurology, 2015, 74, 2-14.	0.9	44
38	Positron Emission Tomography to Elucidate Pharmacokinetic Differences of Regioisomeric Retinoid X Receptor Agonists. ACS Medicinal Chemistry Letters, 2015, 6, 334-338.	1.3	14
39	Clinical presentation of axial myopathy in two siblings with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). BMC Neurology, 2015, 15, 18.	0.8	7
40	New type of encephalomyelitis responsive to trimethoprim/sulfamethoxazole treatment in Japan. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e143.	3.1	7
41	Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1487-1492.	0.7	7
42	Neurofilament light mutation causes hereditary motor and sensory neuropathy with pyramidal signs. Journal of the Peripheral Nervous System, 2014, 19, 311-316.	1.4	25
43	Ectopic calcification: importance of common nanoparticle scaffolds containing oxidized acidic lipids. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 441-450.	1.7	9
44	β2-Glycoprotein l Autoantibodies. , 2014, , 689-698.		0
45	Recombinant Domain V of β2-Glycoprotein I Inhibits the Formation of Atherogenic oxLDL/β2-Glycoprotein I Complexes. Journal of Clinical Immunology, 2014, 34, 669-676.	2.0	11
46	Is atherosclerosis an autoimmune disease?. BMC Medicine, 2014, 12, 47.	2.3	122
47	7-Ketocholesteryl-9-carboxynonanoate enhances ATP binding cassette transporter A1 expression mediated by PPARÎ <sup>3</sup> in THP-1 macrophages. Atherosclerosis, 2014, 234, 461-468.	0.4	5
48	Partial Deficiency of Emerin Caused by a Splice Site Mutation in <i>EMD</i> . Internal Medicine, 2014, 53, 1563-1568.	0.3	5
49	Familial Clusters of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. PLoS ONE, 2014, 9, e86144.	1.1	20
50	A purification system for 64Cu produced by a biomedical cyclotron for antibody PET imaging. Journal of Radioanalytical and Nuclear Chemistry, 2013, 298, 295-300.	0.7	10
51	Novel mutation in the replication focus targeting sequence domain of <i><scp>DNMT1</scp></i> causes hereditary sensory and autonomic neuropathy <scp>IE</scp> . Journal of the Peripheral Nervous System, 2013, 18, 89-93.	1.4	29
52	7-Ketocholesteryl-9-carboxynonanoate enhances the expression of ATP-binding cassette transporter A1 via CD36. Atherosclerosis, 2013, 226, 102-109.	0.4	8
53	Laminin-1 (LM-111) in preeclampsia and systemic lupus erythematosus. Autoimmunity, 2013, 46, 14-20.	1.2	6
54	Hereditary sensory and autonomic neuropathy type IID caused by an <i>SCN9A</i> mutation. Neurology, 2013, 80, 1641-1649.	1.5	59

#	Article	IF	CITATIONS
55	Novel mutations identified in patients with a mild phenotype of Ullrich congenital muscular dystrophy through targeted next-generation sequencing. Neurology and Clinical Neuroscience, 2013, 1, 148-153.	0.2	0
56	Chronic Multiple Sclerosis Lesions: Characterization with High-Field-Strength MR Imaging. Radiology, 2012, 262, 206-215.	3.6	109
57	β2-glycoprotein I and oxidative inflammation in early atherogenesis: A progression from innate to adaptive immunity?. Autoimmunity Reviews, 2012, 12, 241-249.	2.5	48
58	Minocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease. Retrovirology, 2012, 9, 16.	0.9	19
59	A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy. Nature Medicine, 2011, 17, 604-609.	15.2	267
60	Histopathological differences between human T-lymphotropic virus type 1-positive and human T-lymphotropic virus type 1-negative polymyositis. Clinical and Experimental Neuroimmunology, 2011, 2, 12-24.	0.5	4
61	A Possible Mechanism of Autoimmuneâ€Mediated infertility in Women with Endometriosis. American Journal of Reproductive Immunology, 2011, 66, 90-99.	1.2	24
62	Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2011, 6, 354-361.	2.1	98
63	Neural bystander damage by infiltrating virus-infected T cells and the cytotoxic T lymphocytes in HTLV-I-associated neurological disease. Retrovirology, 2011, 8, .	0.9	0
64	Recombinant domain V of Â2-glycoprotein I inhibits the formation of a 7-ketocholesteryl-9-carboxynonanoate and Â2-glycoprotein I complex. Journal of Biochemistry, 2011, 149, 35-42.	0.9	4
65	Neuroimmunity of HTLV-I Infection. Journal of NeuroImmune Pharmacology, 2010, 5, 310-325.	2.1	60
66	Oxidized-LDL/β2-Glycoprotein I Complexes Are Associated With Disease Severity and Increased Risk for Adverse Outcomes in Patients With Acute Coronary Syndromes. American Journal of Clinical Pathology, 2010, 133, 737-743.	0.4	59
67	Rosuvastatin Treatment is Associated with a Decrease of Serum Oxidised Low-Density Lipoprotein/Beta2-Glycoprotein I Complex Concentration in Type 2 Diabetes. British Journal of Diabetes and Vascular Disease, 2010, 10, 292-299.	0.6	10
68	7-Ketocholesteryl-9-carboxynonanoate induced nuclear factor-kappa B activation in J774A.1 macrophages. Life Sciences, 2010, 87, 651-657.	2.0	17
69	Newer Antiphospholipid Antibodies Predict Adverse Outcomes in Patients With Acute Coronary Syndrome. American Journal of Clinical Pathology, 2009, 132, 613-620.	0.4	41
70	High Expression of CD244 and SAP Regulated CD8+ T Cell Responses of Patients with HTLV-I Associated Neurologic Disease. PLoS Pathogens, 2009, 5, e1000682.	2.1	29
71	New impacts of cutaneous lupus erythematosus for global standard concepts. Autoimmunity Reviews, 2009, 8, 439-440.	2.5	2
72	The immunology of atherothrombosis in the antiphospholipid syndrome: Antigen presentation and lipid intracellular accumulation. Autoimmunity Reviews, 2009, 8, 500-505.	2.5	28

#	Article	lF	CITATIONS
73	Autoimmunity, Infectious Immunity, and Atherosclerosis. Journal of Clinical Immunology, 2009, 29, 714-721.	2.0	33
74	Atherosclerosis and Autoimmunity. Clinical Reviews in Allergy and Immunology, 2009, 37, 1-3.	2.9	4
75	Immunogenic Oxidized Low-density Lipoprotein/β2-glycoprotein I Complexes in the Diagnostic Management of Atherosclerosis. Clinical Reviews in Allergy and Immunology, 2009, 37, 12-19.	2.9	17
76	Chronic Infections and Atherosclerosis. Clinical Reviews in Allergy and Immunology, 2009, 37, 44-48.	2.9	42
77	Atherosclerosis in autoimmune diseases. Current Rheumatology Reports, 2009, 11, 61-69.	2.1	25
78	Nicked β2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property. Blood, 2009, 114, 2553-2559.	0.6	23
79	Selfâ€interaction of soluble and surfaceâ€bound β <sub>2</sub> â€glycoprotein I and its enhancement by lupus anticoagulants. FEBS Letters, 2008, 582, 3308-3312.	1.3	3
80	Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle. Autoimmunity Reviews, 2008, 7, 214-222.	2.5	26
81	Oxidation of LDL and its clinical implication. Autoimmunity Reviews, 2008, 7, 558-566.	2.5	195
82	Atherosclerosis in primary antiphospholipid syndrome. Expert Review of Clinical Immunology, 2008, 4, 53-60.	1.3	3
83	Expression of the Heparin-Binding Growth Factor Midkine in the Cerebrospinal Fluid of Patients with Neurological Disorders. Internal Medicine, 2008, 47, 83-89.	0.3	8
84	Inclusion Body Myositis Associated With Human T-Lymphotropic Virus-Type I Infection. Journal of Neuropathology and Experimental Neurology, 2008, 67, 41-49.	0.9	47
85	Postinfectious immunodeficiency and autoimmunity: pathogenic and clinical values and implications. Expert Review of Clinical Immunology, 2007, 3, 323-331.	1.3	4
86	The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. Journal of Lipid Research, 2007, 48, 768-781.	2.0	61
87	Î <sup>2</sup> 2-GLYCOPROTEIN I AUTOANTIBODIES. , 2007, , 687-693.		1
88	Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein l in patients with antiphospholipid syndrome. Blood, 2007, 110, 4312-4318.	0.6	52
89	Different pattern of HSP47 expression in skeletal muscle of patients with neuromuscular diseases. Neuromuscular Disorders, 2007, 17, 221-226.	0.3	9
90	Antibodies against heat shock protein 60 derived from Helicobacter pylori: Diagnostic implications in cardiovascular disease. Journal of Autoimmunity, 2007, 29, 106-115.	3.0	46

#	Article	IF	CITATIONS
91	Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: Implications on the development of antiphospholipid syndrome. Journal of Autoimmunity, 2007, 29, 164-173.	3.0	51
92	Elevated Serum sFlt-1/Ang-2 Ratio in Women with Preeclampsia. Nephron Clinical Practice, 2007, 106, c43-c50.	2.3	29
93	Satoyoshi syndrome has antibody against brain and gastrointestinal tissue. Muscle and Nerve, 2007, 36, 400-403.	1.0	18
94	Determination of Oxidized Low-Density Lipoproteins (ox-LDL) versus ox-LDL/beta2GPI Complexes for the Assessment of Autoimmune-Mediated Atherosclerosis. Annals of the New York Academy of Sciences, 2007, 1109, 303-310.	1.8	20
95	Antiphospholipid Antibodies in Patients with Coronary Artery Disease: New Cardiac Risk Factors?. Annals of the New York Academy of Sciences, 2007, 1108, 466-474.	1.8	15
96	Subclinical Atherosclerosis in Primary Antiphospholipid Syndrome. Annals of the New York Academy of Sciences, 2007, 1108, 475-480.	1.8	32
97	Atherogenic Antiphospholipid Antibodies in Antiphospholipid Syndrome. Annals of the New York Academy of Sciences, 2007, 1108, 489-496.	1.8	12
98	Chronic Infections and Atherosclerosis. Annals of the New York Academy of Sciences, 2007, 1108, 594-602.	1.8	39
99	Accelerated Atheroma in the Antiphospholipid Syndrome. Rheumatic Disease Clinics of North America, 2006, 32, 537-551.	0.8	11
100	MRI studies of spinal visceral larva migrans syndrome. Journal of the Neurological Sciences, 2006, 249, 7-12.	0.3	41
101	Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Progress in Lipid Research, 2006, 45, 466-486.	5.3	143
102	Binding of β2–glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood, 2005, 105, 1552-1557.	0.6	92
103	Oxidized Low-Density Lipoprotein/β2-Glycoprotein I Complexes and Autoantibodies in Patients with Type 2 Diabetes Mellitus. Annals of the New York Academy of Sciences, 2005, 1051, 97-103.	1.8	33
104	Pregnancy Loss and Endometriosis: Pathogenic Role of Anti-Laminin-1 Autoantibodies. Annals of the New York Academy of Sciences, 2005, 1051, 174-184.	1.8	47
105	OxLDL/β2GPI Complexes and Autoantibodies in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, and Antiphospholipid Syndrome: Pathogenic Implications for Vascular Involvement. Annals of the New York Academy of Sciences, 2005, 1051, 313-322.	1.8	71
106	The Role of Innate and Adaptive Immunity to Oxidized Low-Density Lipoprotein in the Development of Atherosclerosis. Annals of the New York Academy of Sciences, 2005, 1051, 442-454.	1.8	30
107	Intravenous Immunoglobulin and Atherosclerosis. Clinical Reviews in Allergy and Immunology, 2005, 29, 311-320.	2.9	11
108	Significance of valine/leucine247 polymorphism of ?2-glycoprotein I in antiphospholipid syndrome: Increased reactivity of anti-?2-glycoprotein I autoantibodies to the valine247 ?2-glycoprotein I variant. Arthritis and Rheumatism, 2005, 52, 212-218.	6.7	56

#	Article	IF	CITATIONS
109	Antigenic structures recognized by anti-β2-glycoprotein I auto-antibodies. International Immunology, 2005, 17, 1533-1542.	1.8	31
110	Characterization of a Murine Anti-laminin-1 Monoclonal Antibody (AK8) Produced by Immunization with Mouse-derived Laminin-1. Clinical and Developmental Immunology, 2005, 12, 67-73.	3.3	8
111	Chemical Xenobiotics and Mitochondrial Autoantigens in Primary Biliary Cirrhosis: Identification of Antibodies against a Common Environmental, Cosmetic, and Food Additive, 2-Octynoic Acid. Journal of Immunology, 2005, 174, 5874-5883.	0.4	176
112	Research around β2-glycoprotein I: A major target for antiphospholipid antibodies. Autoimmunity, 2005, 38, 377-381.	1.2	21
113	Unilateral toe-walking secondary to intramuscular hemangioma in the gastrocnemius. Neurology, 2005, 65, E15-E15.	1.5	10
114	Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases. Circulation, 2005, 112, 3337-3347.	1.6	484
115	Increase of Serum Angiopoietin-2 During Pregnancy Is Suppressed in Women With Preeclampsia. American Journal of Hypertension, 2005, 18, 1181-1188.	1.0	44
116	Oxidized Low-Density Lipoprotein/β <sub>2</sub> -Glycoprotein I Complexes and Autoantibodies to oxLig-1/β <sub>2</sub> -Glycoprotein I in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. American Journal of Clinical Pathology, 2004, 121, 426-436.	0.4	51
117	Are Oxidized LDL/β2-glycoprotein I Complexes Pathogenic Antigens in Autoimmune-mediated Atherosclerosis?. Clinical and Developmental Immunology, 2004, 11, 103-111.	3.3	48
118	Anti-laminin-1 Autoantibodies, Pregnancy Loss and Endometriosis. Clinical and Developmental Immunology, 2004, 11, 261-266.	3.3	23
119	Clinical Significance of Serum Oxidized Low-Density Lipoprotein/β <sub>2</sub> -Glycoprotein I Complexes in Patients with Chronic Renal Diseases. Nephron Clinical Practice, 2004, 98, c15-c24.	2.3	36
120	Are Anti–Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective?. Circulation, 2004, 110, 2552-2558.	1.6	143
121	Nicked Â2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood, 2004, 103, 3766-3772.	0.6	54
122	IMMUNOLOGY OF ANTI-PHOSPHOLIPID ANTIBODIES AND COFACTORS. , 2004, , 1081-1105.		7
123	Multiple autoantibodies associated with autoimmune reproductive failure. Journal of Assisted Reproduction and Genetics, 2003, 20, 53-57.	1.2	13
124	Immunization of Naive Mice with Mouse Laminin-1 Affected Pregnancy Outcome in a Mouse Model. American Journal of Reproductive Immunology, 2003, 50, 159-165.	1.2	23
125	Atherogenic autoantigen: oxidized LDL complexes with ?2-glycoprotein I. Immunobiology, 2003, 207, 17-22.	0.8	28
126	Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. Journal of Lipid Research, 2003, 44, 716-726.	2.0	165

#	Article	IF	CITATIONS
127	An association of IgG anti-laminin-1 autoantibodies with endometriosis in infertile patients. Human Reproduction, 2003, 18, 544-549.	0.4	60
128	Anti-idiotypes to Oxidized LDL Antibodies in Intravenous Immunoglobulin PreparationsPossible Immunomodulation of Atherosclerosis. Autoimmunity, 2003, 36, 91-97.	1.2	30
129	ï‰-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. Journal of Lipid Research, 2002, 43, 1486-1495.	2.0	64
130	The Orientation of β2GPI on the Plate is Important for the Binding of Anti-β2GPI Autoantibodies by ELISA. Journal of Autoimmunity, 2002, 18, 289-297.	3.0	38
131	Anti-β 2 -Glycoprotein I Autoantibodies and Atherosclerosis. International Reviews of Immunology, 2002, 21, 51-66.	1.5	15
132	Autoantibody-mediated atherosclerosis. Autoimmunity Reviews, 2002, 1, 348-353.	2.5	46
133	Expression of vascular endothelial growth factor in tuberculous meningitis. Journal of the Neurological Sciences, 2001, 186, 75-79.	0.3	46
134	IgG Anti-laminin-1 Autoantibody and Recurrent Miscarriages. American Journal of Reproductive Immunology, 2001, 45, 232-238.	1.2	39
135	Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis and Rheumatism, 2000, 43, 1982-1993.	6.7	299
136	Proteolytic cleavage of $\hat{l}^2$ 2-glycoprotein I: reduction of antigenicity and the structural relationship. International Immunology, 2000, 12, 1183-1192.	1.8	35
137	β2-glycoprotein l–anti-β2-glycoprotein I Interaction. Journal of Autoimmunity, 2000, 15, 97-100.	3.0	30
138	β2-glycoprotein I deficiency:. Atherosclerosis, 2000, 152, 337-346.	0.4	77
139	Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis. Journal of the Neurological Sciences, 2000, 173, 45-52.	0.3	75
140	?2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis and Rheumatism, 1999, 42, 167-174.	6.7	58
141	A chimeric antibody with the human ?1 constant region as a putative standard for assays to detect IgG ?2-glycoprotein I-dependent anticardiolipin and anti-?2-glycoprotein I antibodies. Arthritis and Rheumatism, 1999, 42, 2461-2470.	6.7	91
142	Antiphospholipid Syndrome Internal Medicine, 1999, 38, 170-173.	0.3	1
143	Use of various methods for anticardiolipin detection in the updated American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: Comment on the letter by Hochberg. Arthritis and Rheumatism, 1998, 41, 1326-1327.	6.7	6
144	DNA-alginate complex recognized by autoantibodies against DNA. International Journal of Biological Macromolecules, 1997, 20, 75-77.	3.6	33

#	Article	IF	CITATIONS
145	Participation of α <sub>Ilb</sub> β <sub>3</sub> in Platelet Microparticle Generation by Collagen plus Thrombin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 31-37.	0.5	5
146	Phospholipid-Dependent AntiBETA.2-Glycoprotein I (.BETA.2-GPI) Antibodies and Antiphospholipid Syndrome Internal Medicine, 1996, 35, 105-110.	0.3	12
147	Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1996, 39, 1466-1474.	6.7	210

148 Anticardiolipin Antibodies in Patients With Pregnancy Loss Induce Factor Xa Production in the

#	Article	IF	CITATIONS
163	Detection and clinical significance of acetoneinsoluble liver cell membrane antigen in sera of patients with chronic active liver diseases. Gastroenterologia Japonica, 1985, 20, 37-47.	0.4	4
164	Enzyme Immunoassay for Mabuterol, A Selective β2-Adrenergic Stimulant in the Trachea. Journal of Immunoassay, 1985, 6, 261-276.	0.3	10
165	An experimental model of nephritis induced by calf serum injection in mice The Japanese Journal of Pharmacology, 1984, 36, 223-234.	1.2	4